Dexcom– tag –
-
Dexcom G7 15-Day Continuous Glucose Monitor Authorized by Health Canada, Stelo CGM Cleared for Pediatric OTC Use by U.S. FDA
Business Wire, MarketScreener, CureCapture, Oura Member Care USA, Canada Overview Dexcom's G7 15-day continuous glucose monitoring (CGM) system has received Health Canada authorization for adults aged 18 and older, extending wear time to... -
Diabeloop and Vicentra Launch Smartphone-Controlled DBLG2 System Integrated with Dexcom G7 CGM in Europe
Press Release Hub (PA Media) UK Overview Diabeloop and Vicentra have jointly launched the smartphone-controlled DBLG2 system in the European market. This system integrates Vicentra's Kaleido insulin patch pump with the Dexcom G7 continuo... -
FDA Clears Dexcom Stelo Glucose Biosensor as First Over-the-Counter CGM for Insulin-Naive Children Aged 2 and Up
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted the first over-the-counter (OTC) clearance for Dexcom's Stelo Glucose Biosensor System, expanding its use to insulin-naive children aged two and older. This la... -
Dexcom Stelo Secures First FDA OTC CGM Approval, Abbott Advances Freestyle Libre 3 Plus with 15-Day Wear & AID Compatibility
CNET USA Overview Dexcom's Stelo achieved the first FDA approval for an over-the-counter Continuous Glucose Monitor (CGM) in 2024, significantly broadening access for general consumers. Concurrently, Abbott's Freestyle Libre 3 Plus enter... -
DexCom Expands Stelo Glucose Biosensor to Non-Insulin-Using Children, Launches Redesigned App in US July 2026
WealthMagik (via Earnings Stability Report) USA Overview DexCom announced FDA approval to expand the Stelo Glucose Biosensor to non-insulin-using children aged 2 and older, aligning with the company's mission to make glucose sensing more... -
Smartwatches Revolutionize Blood Sugar Management: Dexcom G7 and FreeStyle Libre Enhance Apple Watch Integration, Expanding AI-Driven Ecosystem
TechRepublic USA Overview Smartwatches hold the potential to transform glucose tracking, but current advancements rely on the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and regulated healthcare tech... -
GoodRx Compares Leading CGMs: Dexcom G7 10-Day Sensor Emerges as Sole FDA-Approved Device for Children Ages 2+
GoodRx USA Overview According to a GoodRx comparison report, the Dexcom G7 10-day sensor is FDA-approved for adults and children aged 2 and older, while the Dexcom G7 15-day sensor and Eversense 365 are approved exclusively for adults ag... -
The Rise of Finger-Prick-Free Glucose Monitoring: Dexcom Stelo, Abbott Lingo, and the CGM Revolution in Metabolic Health
Mattioli 1885 イタリア Overview The U.S. FDA has approved a new generation of finger-prick-free continuous glucose monitors (CGMs) that measure interstitial fluid glucose and transmit real-time data to smartphones, largely eliminating da... -
FDA Clears Dexcom Stelo as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children (Ages 2+)
HCPLive USA Overview The FDA has approved Dexcom's Stelo Glucose Biosensor System for over-the-counter (OTC) use in children aged 2 years and older who do not use insulin. This marks Stelo as the first OTC continuous glucose monitoring (... -
Dexcom Advances ‘Glucose Biosensing for All’ Vision with Pediatric Clearance for Stelo Biosensor and Relaunch of Redesigned App
Business Wire USA Overview Dexcom announced key milestones at Aspen Ideas: Health, including pediatric clearance for its Stelo Glucose Biosensor and the July launch of a redesigned Stelo app for Apple and Android users. These advancement...
